Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Document Type
- Journal article (21)
- Doctoral Thesis (1)
Keywords
- multiple myeloma (13)
- refractory (4)
- relapse (4)
- 18F-FDG PET/CT (2)
- Multiple myeloma (2)
- daratumumab (2)
- extramedullary disease (2)
- immunotherapy (2)
- 11C-Methionine PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- BRAF mutation (1)
- Bauchspeicheldrüsenkrebs (1)
- CAR T cell (1)
- CD319 (1)
- CD38 (1)
- COVID-19 (1)
- CS1 (1)
- Capicua transcriptional repressor (1)
- Cocktail (1)
- Colonkrebs (1)
- Dara-KDT-P(A)CE (1)
- Drug resistance (1)
- Extramedullary disease (1)
- Fluoreszenzaktivierter Zellsortierer (1)
- Humane Antikörper (1)
- Hybridom (1)
- IgM isotyp (1)
- Immuncytochemie (1)
- Immunfluoreszenz (1)
- Immunglobulin M (1)
- Immunotherapy (1)
- Immuntherapie (1)
- Krebs <Medizin> (1)
- LM-1 (1)
- MOR202 (1)
- Monoklonaler Antikörper (1)
- NORM-1 (1)
- Pathologie (1)
- Pom‐PAD‐Dara (1)
- SAM-6 (1)
- actin (1)
- acute myeloid leukaemia (1)
- antigen loss (1)
- apoptosis (1)
- artificial intelligence (1)
- bortezomib (1)
- carfilzomib (1)
- cell binding (1)
- cell staining (1)
- clinical imaging (1)
- clinical trial (1)
- complement system (1)
- cytogenetics (1)
- cytotoxicity (1)
- diffusion weighted mri (1)
- enzyme-linked immunoassays (1)
- extramedullary (1)
- extramedullary hematopoiesis (1)
- high risk (1)
- human antibodies (1)
- immune control (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- induction regimen (1)
- kidney (1)
- lenalidomide (1)
- management (1)
- mantle cell lymphoma (1)
- metabolic tumor volume (MTV) (1)
- methionine (1)
- minimal residual disease (1)
- monoclonal antibody (1)
- natural language processing (1)
- obinutuzumab (1)
- ontology (1)
- pancreatic cancer (1)
- pathophysiology (1)
- patients with multiple myeloma (1)
- pattern (1)
- plasma cell disorder (1)
- plasma cells (1)
- progression (1)
- radiogenomics (1)
- real world evidence (1)
- renal failure (1)
- risk stratification (1)
- salvage (1)
- smoldering myeloma (1)
- spatial heterogeneity (1)
- spleen (1)
- targeted therapy (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- toxicity (1)
- transient regulatory T-cell targeting (1)
- translational research (1)
- tumor burden (1)
- venetoclax (1)
Institute
- Medizinische Klinik und Poliklinik II (21)
- Klinik und Poliklinik für Nuklearmedizin (6)
- Pathologisches Institut (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (4)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
- Institut für Informatik (1)
- Institut für Virologie und Immunbiologie (1)
- Lehrstuhl für Orthopädie (1)
Sonstige beteiligte Institutionen
\(^{11}\)C-methionine (\(^{11}\)C-MET) is a new positron emission tomography (PET) tracer for the assessment of disease activity in multiple myeloma (MM) patients, with preliminary data suggesting higher sensitivity and specificity than \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG). However, the value of tumor burden biomarkers has yet to be investigated. Our goals were to corroborate the superiority of \(^{11}\)C-MET for MM staging and to compare its suitability for the assessment of metabolic tumor burden biomarkers in comparison to \(^{18}\)F-FDG. Twenty-two patients with newly diagnosed, treatment-naïve symptomatic MM who had undergone \(^{11}\)C-MET and \(^{18}\)F-FDG PET/CT were evaluated. Standardized uptake values (SUV) were determined and compared with total metabolic tumor volume (TMTV) for both tracers: total lesion glycolysis (TLG) and total lesion \(^{11}\)C-MET uptake (TLMU). PET-derived values were compared to Revised International Staging System (R-ISS), cytogenetic, and serologic MM markers such as M component, beta 2 microglobulin (B2M), serum free light chains (FLC), albumin, and lactate dehydrogenase (LDH). In 11 patients (50%), \(^{11}\)C-MET detected more focal lesions (FL) than FDG (p < 0.01). SUVmax, SUVmean, SUVpeak, TMTV, and TLMU were also significantly higher in \(^{11}\)C-MET than in \(^{18}\)F-FDG (p < 0.05, respectively). \(^{11}\)C-MET PET biomarkers had a better correlation with tumor burden (bone marrow plasma cell infiltration, M component; p < 0.05 versus p = n.s. respectively). This pilot study suggests that \(^{11}\)C-MET PET/CT is a more sensitive marker for the assessment of myeloma tumor burden than \(^{18}\)F-FDG. Its implications for prognosis evaluation need further investigation.
This study aimed to explore the correlation between imaging patterns and clinical features in patients with smoldering multiple myeloma (SMM) who simultaneously underwent 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor positron emission tomography/computed tomography (PET/CT). We retrieved and analyzed clinical characteristics and PET imaging data of 10 patients with SMM. We found a significant correlation between bone marrow (BM) plasma cell (PC) infiltration and mean standardized uptake values (SUV\(_{mean}\)) of lumbar vertebrae L2-L4 on 11C-Methionine PET/CT scans (r = 0.676, p = 0.031) and 68Ga-Pentixafor PET/CT scans (r = 0.839, p = 0.002). However, there was no significant correlation between BM involvement and SUV\(_{mean}\) of lumbar vertebrae L2-L4 on 18F-FDG PET/CT scans (r = 0.558, p = 0.093). Similarly, mean target-to-background ratios (TBR\(_{mean}\)) of lumbar vertebrae L2-L4 also correlated with bone marrow plasma cell (BMPC) infiltration in 11C-Methionine PET/CT (r = 0.789, p = 0.007) and 68Ga-Pentixafor PET/CT (r = 0.724, p = 0.018) PET/CT. In contrast, we did not observe a significant correlation between BMPC infiltration rate and TBR\(_{mean}\) in 18F-FDG PET/CT (r = 0.355, p = 0.313). Additionally, on 11C-Methionine PET/CT scans, we found a significant correlation between BMPC infiltration and TBR\(_{max}\) of lumbar vertebrae L2-L4 (r = 0.642, p = 0.045). In conclusion, 11C-Methionine and 68Ga-Pentixafor PET/CT demonstrate higher sensitivity than 18F-FDG PET/CT in detecting BM involvement in SMM.